Home Blog Page 429

XtalPi Holdings Announces Full Year 2025 Annual Results

HONG KONG, March 25, 2026 /PRNewswire/ —

Financial Highlights:

  • Revenues for year 2025 were RMB802.6 million, representing a year-over-year increase of 201.2%.
  • Net profit for year 2025 reached reached RMB 134.6 million, while adjusted net profit amounted to RMB 258.2 million, making the Group’s first full year of profitability and making it the first profitable AI4S company listed on the H-share market.
  • As of December 31, 2025, the Group’s total cash balance[1] amounted to RMB 7,068.6 million. In 2026, the Group raised further net proceeds of RMB 2,536.8 million through the issuance of new convertible bonds.

Key Business Milestones:

  • Incubated and advanced more than five global first-in-class/best-in-class innovative pipelines to clinical and/or IND-enabling stages, spanning oncology, autoimmune diseases, neurodegenerative disorders, and chronic diseases.
  • Secured multiple landmark collaborations with cumulative contract values reaching tens of billions of RMB, further solidifying the Group’s leadership in AI applications.
  • The number of revenue-generating clien count[2] in 2025 grew by 62% year-over-year. To date, the Group has cumulatively covered 17 of the world’s top 20 pharmaceutical companies, successfully delivering across multiple scenarios and earning recognition from leading global clients.
  • The Group has developed over 200 industry-specific AI models to date. In 2025, the Group further expanded its novel drug innovation platforms, into molecular glues, peptides, and oligonucleotides, reinforcing its full-stack capability moat.
  • AI agents independently orchestrated tens of thousands of compound synthesis experiments every week, enabling a fully closed-loop development process.
  • The Group successfully expanded into new sectors such as new materials,consumer and health & wellness.
  • During the Reporting Period, the Group was also included in the MSCI China Small Cap Index, the MSCI China Index, and the HKex Tech 100 Index, reflecting strong recognition from international capital markets of the Group’s investment value and industry leadership.

R&D Progress: Deep Integration of AI, Robotics, and Multi -Agent – How the Flywheel Effect is Reshaping the R&D Paradigm

1.  Multi-Agent Matrix: Acting as Intelligent “Project Managers” to Drive Fully Autonomous Workflows

Serving as the central orchestration hub of the development flywheel, a multi-agent system autonomously break down research objectives, coordinate multiple AI models, and manage closed-loop robotic experiments. Leveraging the Group’s proprietary AI models, robotics laboratories, and extensive data assets, the Group is building an end-to-end intelligent agent ecosystem that has been deployed across both internal workflows and external application scenarios.

1)     The Group is building an integrated agent system covering the entire R&D workflow, incorporating Agentic Genius, X-Buddy, PatSight, MolAgent, the Vast Agent virtual compound library, synthesis robots, and a robotics orchestration platform, enabling autonomous decision-making across the full process from procurement and experiment execution to reaction optimization, data management and validation. Currently, the Compnay’s AI agents independently orchestrate tens of thousands of compound synthesis experiments per week, significantly enhancing throughput and data accumulation efficiency, and establishing a closed-loop R&D system covering small molecule drug design, high-throughput automated synthesis, and cloosed-loop data feedback.

2)     During the Reporting Period, the Group partnered with a leading global pharmaceutical company to deploy an autonomous reaction condition screening system integrating a multi-agent system, robotics laboratories, and chemistry AI models to establish a closed-loop workflow spanning AI-driven condition recommendation, autonomous experimental parameter design, high-throughput robotic execution, and reaction optimization. Trained on hundreds of thousands of experimental data points, the system supports development objectives expressed in natural language, with robotic solutions precisely performing operations such as reagent dispensing, temperature control, and analytical testing, significantly improving data consistency and experimental reliability, while providing a scalable and replicable solution for intelligent R&D transformation.

[1] Cash balance includes cash and cash equivalents, bankdeposits, current portion of financial assets at fair value through profit or loss, and restricted cash, as of 31 December 2025.

[2] Not inclusive of customers of Shanghai Siwei Medical Technology Co.,Ltd.

2.  AI Models: Reinforcing the “Expert Brain” and Expanding into Novel Drugs

By the end of 2025, the Group had developed over 200 industry-specific AI models, covering the entire workflow from target discovery to preclinical candidate screening. During the Reporting Period, the Group’s AI models achieved systematic results in deepening strategic collaborations, upgrading core models, and expanding into novel drugs.

1)     The Group continued to deepen industry partnerships and upgrade our AI-driven drug discovery models, building a data closed loop from molecular design to biological testing. By integrating molecular dynamics simulation data as a core input, we have embeded dynamic physical-based principles into our AI models, equipping them to interpret the nature of protein-protein interactions and providing strong support for tackling ‘undruggable’ targets. In molecular activity prediction, we further advanced our strategic collaboration with Pfizer, launching a next-generation molecular simulation platform in 2025. By combining the precision of physics-based algorithms with the speed and scalability of AI, this platform significantly improves simulation efficiency, accuracy, and chemical space coverage to accelerate small molecule drug discovery.

2)     The Group’s self-developed generative AI platform for protein therapeutics, XenProT™, introduced the XMPNN inverse folding design algorithm, achieving world-leading performance in evaluations on public benchmark datasets by leverageing high-quality data and proprietary domain knowledge, and demonstrating its value across multiple challenging pipeline projects, with its bispecific antibody design capabilities recognized by leading global pharmaceutical companies. Meanwhile, XtalFold® launched its Ultra mode, boosting the accuracy of antigen–antibody complex structure prediction by approximately 10 percentage points, and was selected as one of the “Top 10 AI Innovation Technologies (Products)” at WAIC.

3)     Building AI Platforms for Novel Drugs – Establishing Leadership in Emerging Frontiers.

  • Molecular Glue Platform: In 2025, the Group debuted a molecular glue development platform with AI, robotics and multi-agent as core drivers, built around the dual-path strategy of “E3 anchoring” and “target protein anchoring,” leveraging AI-driven learning of protein–protein interaction patterns alongside ultra-large chemical space exploration and an automated DMTA loop to significantly enhance R&D efficiency. The platform has assembled virtual and chemically diverse molecular entity libraries exceeding one million compounds, generating high-active, highly selective, patent-novel Hit molecules across multiple targets, while continuously expanding new system modules and Direct-to-Biology capabilities.
  • Peptide Platform PepiX™: In 2025, the Group’s peptide platform PepiX™ integrated generative AI molecular design, automated synthesis, a trillion-scale peptide library, and high-throughput screening to establish an iterative “AI design-to-synthesis validation” system, enabling high efficiency and success rates in peptide drug R&D. The platform benefits from a library of over 2,000 non-natural amino acid monomers, achieving internationally leading performance in oral peptide prediction and MHC-I/II antigen presentation prediction, and was showcased at AACR2025 while receiving multiple industry recognitions. Core pipeline programs are progressing steadily, with continued advances in brain-penetrating peptide delivery, glucose-lowering, anti-obesity, and uric acid-lowering programs, supporting future regulatory submissions and commercialization.
  • Nucleic Acid Platform Kodexia™: In 2025, the Group built a globally leading AI-powered platform for siRNA sequence discovery and chemical modification, establishing an end-to-end closed loop encompassing sequence screening, modification recommendation and optimization, and functional validation. Proprietary models enable precise siRNA modeling and outperform Advanced ESC modification patterns in most scenarios. Meanwhile, the Group is advancing in-vivo efficacy prediction models, extra-hepatic delivery platfoms, and dual-target siRNA platform development, while its breakthrough research mRNA2vec was presented at AAAI 2025, significantly improving mRNA sequence expression and stability.
  • Virtual Cell Platform: In 2025, the Group strategically incubated Boundless Evolution, a venture dedicated to building a virtual cell platform powered by biological data. Boundless Evolution is currently securing early-stage financing to drive its next phase of research and development.

3.  Robotic Laboratory (Physical AI): Building “Precision Hands” to Redefine the Experimental Paradigm

During the Reporting Period, the Group continued to drive technological breakthroughs across its robotic laboratories, achieving several key milestones. “NeoDispenser” design overcomes key challenges in robotic laboratory technology, and has gained strong receognition from leading global customers. Key technical features include:

1)     Advanced Visual Perception: Features cutting-edge visual perception algorithms that analyze powder characteristics in real time, enabling precise identification and handling of different powder types.

2)     Intelligent Database: Integrates a comprehensive powder attribute database with strong learning capabilities that continuously improves powder handling strategies.

3)     Powder Analysis Foundation Model: Powered by a specialized AI model trained and fine-tuned on diverse powder datasets to accurately predict powder properties and behavior.

4)     Seamless Robot Integration: Seamlessly connects with powder aliquoting and other robotic systems, adjusting parameters and control strategies in real-time based on visual feedback.

4.  High-Quality Data Analysis and Accumulation: Continuous “Fuel” for the AI Flywheel

The Group has established an industry-leading biomedical data asset system and an open development data infrastructure platform, providing robust data support for the continuous operation of the AI flywheel.

1)     Multimodal Data Mining Infrastructure: The Group’s multimodal Layout model achieves 95.3% accuracy in document recognition. A self-developed domain-specific 32B LLM surpasses the performance of GPT-4o, delivering both “data localization” and cost efficiency advantages. The OCSR optical chemical structure recognition model has reached industry-leading state-of-the-art performance.

2)     High-Quality Chemical Reaction Data Platform: The Group has developed a data-mining agent for the fine-grained extraction of reaction-step-level data with >95% recognition accuracy, having structured hundreds of thousands of patents to build a massive high-quality reaction dataset that underpins AI models and robotic laboratry experiment training.

3)     High-Quality Large Molecule Data Platform: The Group has developed an antibody data- mining agent, achieving >99% extraction accuracy for both conventional and VHH antibodies, and 98% accuracy in affinity recognition. The Group have also built large-scale antibody patent databases with amino acid sequences, forming a robust biological data asset moat.

During the Reporting Period, the Group’s data-driven R&D innovation capabilities received national recognition. In 2025, leveraging the “AI + Robotics Empowering Drug R&D Data Element Construction and Application” project, the Group stood out from over 22,000 entries in the national finals of the “Data Elements ×” competition hosted by the National Data Bureau, winning the First Prize.

5.  Consumer Health, New Materials and Agriculture: Strategic Expansion and the Flywheel’s Value Extension

The Group’s “AI + Robotics+Multi-Agent” flywheel approach has been fully validated for drug discovery. Building on this foundation, its core capabilities are now rapidly expanding to areas such as consumer health and new materials, evolving from capability replication to strategic expansion.

1)     Expansion into Consumer Health. Both innovative topical molecules for hair growth and hair retention, developed in-house by the Group,  have completed INCI registration, and the combined product Groland formulation has completed U.S. FDA cosmetic facility registration and product listing. The product currently ranks first on Tmall Global’s new arrivals list within its category and has been featured by several leading fashion media outlets.

2)     Driving a Paradigm Shift in Photovoltaics Development. In January 2026, the Group signed a strategic cooperation agreement with a subsidiary of JinkoSolar (688223.SH) on AI and automation-driven high-throughput R&D for tandem solar cell, jointly establishing the world’s first fully closed-loop intelligent manufactureing line for tandem solar cells, intergrating AI-driven decision-making, robotics execution, and data feedback to accelerate deployment of next-generation photovoltaic technologies, including perovskite-based tandem cells. Leveraging the strengths of both parties, perovskite tandem cells are expected to achieve large-scaled mass production within approximately the next three years, with the Group entitled to share in the commercialization returns.

3)     AI4S in Agriculture. In collaboration with a partner, the Group have validated the successul transformation of thousands of mu (hundreds of hectares) of land, setting a new global benchmark for desert restoration.

Commercialization Progress: Accelerating the Momentum of the AI + Robotics + Multi-Agent Platform, Powering a Flywheel of Scalable Growth

1.  Drug Discovery Solutions: AI + Robotics +Multi-Agent Empowering New Drug Development, Platform Value Continues to Grow

During the Reporting Period, revenue from the Drug Discovery Solutions surged by 418.9%, rising from RMB 103.7 million for the year ended December 31, 2024, to RMB 537.9 million for the year ended December 31, 2025. This growth was driven by multiple factors, including: 1) the rapid expansion of the Group’s antibody business; 2) progression of service-enabled and incubated enterprise innovation pipelines into the validation stage, with multiple projects achieving key delivery milestones.

1)     Key Commercial Milestones: From Pipeline Services to Platform Partnerships, Opening a New Chapter in Global Value Co-Creation 

The Group’s “AI + Robotics + Multi-Agent” platform has been validated at industrial scale and continues to evolve. Building on this, the Group has secured multiple high-value partnerships across small molecules, biologics, and novel drugs, with a client base spanning the world’s leading pharmaceutical companies and pioneering biotechs. The Group’s business model has also successfully evolved from standalone project services to a strategic model of “platform licensing + co-development + milestone revenues”, laying a solid foundation for sustainable growth.

  • Collaboration with DoveTree is progressing smoothly, with joint advancement of the pipeline underway. During the Reporting Period, the Group partnered with Professor Gregory Verdine–founded DoveTree to advance small-molecule development across multiple high-value targets in oncology, autoimmune diseases, and neurological disorders. The pipeline is progressing smoothly and has entered a phase of deepened execution. In parallel, under Professor Verdine’s guidance, the Group and the DoveTree team are establishing a next-generation complex molecule platform to develop therapeutics targeting multiple difficult-to-drug targets.
  • Large molecule collaboration with Eli Lilly on track. In the biologics field, the Group has entered into a multi-target strategic collaboration and platform licensing agreement with Eli Lilly, with a total value of USD 345 million. The project is progressing well.
  • Expanding the Group’s AI peptide platform ecosystem, entering a new phase of scaled collaboration in novel drugs. The Group has extended its proven AI R&D capabilities into novel drug domains including peptides. Its proprietary AI peptide R&D platform PepiX™ has received strong recognition from leading industry partners, achieving multiple commercial milestones.

2)     AI Platform Enabling Pipeline Progress: Broad Disease Coverage, Key Technical Milestones Validated

During the Reporting Period, multiple innovative drug pipelines of the Group’s empowered partners and incubated companies achieved important progress across a range of disease areas, while the Group remains positioned to capture their long-term commercial value and development upside.

  • Empowering “AI + organoid” pipeline breakthroughs for Signet Therapeutics, with the world’s first targeted therapy for diffuse gastric cancer advancing well clinically. The candidate SIGX1094 was co-developed by XtalPi and incubated company Signet. Leveraging a novel “organoid + AI” R&D approach, its Phase I clinical trials demonstrated a good safety and signs of efficacy, with one patient in the 200mg cohort showing a 20% reduction in lesion size and symptom relief. This program has received FDA Orphan Drug and Fast Track Designations, earned a Prix Galien nomination, and is expected to enter Phase II clinical trials in the third quarter of 2026. According to market research institution data, the corresponding market for advanced targeted therapies exceeds several billion USD.
  • Also from this collaboration, a potential first-in-class pan-TEAD inhibitor SIGX2649, for the treatment of solid tumors, has completed preclinical studies, with IND applications to be simultaneously submitted to regulatory authorities in both China and the United States shortly. The drug’s preclinical research has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. The Group works in deep collaboration with Signet, providing core technical support for their pipeline development while sharing in the company’s growth and pipeline value appreciation.
  • Boosting Leman Biotech’s AI-driven metabolic reprogramming platform to deliver clinical breakthroughs across key disease areas. During the Reporting Period, Leman Biotech’s metabolicallyenhanced CD19 CAR-T therapy achieved 100% complete remission in dozens of patients at ultra-low doses in investigator-initiated trials (IITs) for relapsed/refractory lymphoma, leukemia, and moderate-to-severe SLE. In March 2026, it received FDA IND clearance for the relevant indications. Meanwhile, META 10-TILs and multiple metabolism-enhanced CAR-T pipelines have entered IIT stages, with simultaneous filings progressing in both China and the U.S. According to market research insitutions, the global CAR-T cell therapy market is forecast to reach USD 21.8 billion by 2030. The Group has established a deep strategic collaboration with Lemam Biotech to jointly translate R&D outcomes into commercial value.
  • Incubated company METiS TechBio continues to advance its AI-driven drug development platform. In 2025, NETiS launched NanoForge, the world’s first AI nano-delivery platform, establishing a library of tens of millions of ionizable LNPs and an intelligent nano-delivery agent, enabling a fully closed-loop R&D workflow from molecular design to formulation optimization. Leveraging this platform, METiS’s proprietary hepatocellular carcinoma pipeline MTS-105 received the FDA Orphan Drug Designation, while MTS-004 achieved its Phase III primary endpoints, becoming China’s first AI-developed drug and the only PBA therapy to complete Phase III. The Group shares development gains through equity partnerships.
  • Co-developed with Pharma Engine, next-generation PRMT5 inhibitor PEP08 reaches key clinical milestone. PEP08 demonstrates low toxicity and a favorable safety profile, with the ability to cross the blood-brain barrier and inhibit tumor growth, showing strong potential in brain cancer treatment and potential best-in-class efficacy. It has received clinical trial approvals in both Australia and Taiwan, China, and has entered Phase I clinical trials, with the Group retaining economic rights tied to future clinical milestones.
  • Assisting ReviR Therapeutics to reach new milestones in AI-driven rare disease drug development. During the reporting period, RTX-117, China’s first CMT Type 1 innovative drug, achieved simultaneous clinical approvals in both China and the U.S., being granted the FDA Orphan Drug Designation. In 2026, it also obtained China’s NMPA approval to initiate VWM clinical studies and commenced Phase I trials. This small molecule penetrates the blood-brain barrier and exerts its therapeutic effect by modulating the ISR pathway, with potential future expansion into the neurodegenerative disease market. The Group will receive milestone payments along with holding long-term economic rights in the drug.
  • Our collaboration with a leading biopharmaceutical firm continues to deepen with positive outcomes. Of the three innovative drug development projects initaiated prior to 2025, two now have entered the IND-enabling studies, while the third is expected to commence in the first half of 2026. This progress highlights the strong translational efficiency of our platform and our capability to consistently deliver high-quality pipelines. the Group is positioned to capture substantial financial returns in future stages.
  • Empowering a leading biopharmaceutical company’ drive into immunometabolism innovation. During the Reporting Period, META-001-PH received the FDA Orphan Drug and Rare Pediatric Disease Designation, while MP-5342 entered the IND-enabling studies, demonstrating a safety window exceeding 600-fold and significant anti-inflammatory efficacy, with the potential to address the LDH target gap. This pipeline also holds promise for expansion into autoimmune diseases such as multiple sclerosis and atopic dermatitis. According to makret research institutions, the combined global market for these indications is estimated at tens of billions of USD. Clinical trial registration is expected to commence in the fourth quarter of 2026. The Group retains long-term economic rights in the pipeline.

2. AI4S Intelligent Solutions[3]: Scaling from Solutions to Platform- AI + Robotics + Multi- Agent Driving R&D Efficiency Across Domains

During the Reporting Period, revenue from AI4S Intelligent Solutions grew at a rapid pace, rising 62.6% from RMB 162.8 million for the year ended December 31, 2024 to RMB 264.7 million for the year ended December 31, 2025, driven primarily by new strategic initiatives within the business.

The AI4S intelligent solutions business has matured into a fully integrated intelligent R&D system serving biopharmaceuticals and new materials and beyond. By integrating robotics hardware with intelligent algorithms, it enhances R&D efficiency and establishes a next-generation AI4S smart platform centered on AI models, robotic laboratories, and smart agents. The synergy between the two business lines forms a closed-loop ecosystem of “solution deployment, core capability iteration, and platform service delivery.” The Group have officially renamed the Intelligent Robotics Solutions business as “AI4S Intelligent Solutions.”

1)     AI4S Intellignet Robotic Labs: Winning Landmark Clients Across Industries

XtalPi R&D Solutions has been renamed AI4S Intelligent Robotic Labs, which delivers locally deployable intelligent R&D systems to customers. Built around robotic laboratories and AI-driven platforms, these solutions replace manual experimentation to enhance R&D efficiency, improve experimental success rates, and enable the accumulation of high-quality, high-value proprietary data assets. During the Reporting Period, the AI4S Intelligent Robotic Labs business delivered strong performance, mainly driven by the continued progression of the Group’s globalization strategy, with breakthrough commercial progress across both biopharmaceuticals and new materials:

  • Delivering an intelligent workstation for formulation stability testing to BASF, a global chemical industry leader
  • Delivery to a globally leading pharmaceutical company headquartered in Indianapolis of a NeoDispenser intelligent micro-powder dispensing system and intelligent compound management system
  • Eight-figure RMB agreement with a domestic central state-owned enterprise to provide an intelligent high-throughput platform for novel catalytic materials development
  • Seven-figure RMB agreement with Roche for the delivery of an intelligent compound storage system
  • Seven-figure RMB agreement with Haleon for the delivery of an intelligent sample pre-processing system
  • Eight-figure RMB agreement with JW Pharmaceutical, a Korean pharmaceutical company, to provide an intelligent autonomous drug synthesis and process development system
  • Eight-figure RMB agreement with Liangzhu Laboratory for the delivery of an intelligent full-process biomaterials research platform covering synthesis through testing

2)     AI4S Intelligent Services: End-to-Engd Smart Platform Accelerates Commercialization

The Group’s AI4S Intelligent Services business is built around a core framework of AI models, robotic laboratories, and multi agent, delivering a full-process intelligent R&D service capabilities that spans key stages including raw material supply forecsting, synthesizability prediction to high-throughput screening, separation, and separation and purification. Leveraging the VAST Agent virtual compound library and synthesis robots, the platform also enables rapid delivery and value-added services. In 2025, the Group successfully expanded its customer base to multiple large pharmaceutical enterprises. Its core techology models achieved reaction success rates exceeding 85% in real-world projects, while chemical services recorded an overall service repeat purchase rate of over 75%. Technologies such as spectral analysis and high-throughput condition recommendation have been deployed across multiple client projects and received strong recognition. Looking ahead, AI4S Intelligent Services is well positioned to espport R&D scenarios across pharmaceuticals, chemistry, chemical engineering, mew materials, new energy and more, with a total addressable market potentially worth trillions of US dollars.

[3] During the Reporting Period, in line with its strategic business upgrade and to more accurately reflect its positioning, the Group renamed its “Intelligent Robotics Solutions” segment to “AI for Science (AI4S) Intelligent Solutions.” This segment comprises two core components: the “AI4S Intelligent Robotic Labs” and “AI4S Intelligent Services.

3. Continued Integration of Cross-Border M&A Assets

In March 2026, the Mayor of the Liverpool City Region Steve Rotherham warmly welcomed senior leaders from XtalPi to the region. Since the acquisition of Liverpool ChiroChem (LCC) in 2025 and the subsequent formation of LCC Technologies Ltd., the Group has continued to deepen local engagement, working closely with the city government and innovation partners to explore advantages in scientific talent, laboratory infrastructure, and development sites. Following the acquisition, the Group has integrated LCC’s PACE™ automated chiral chiral-chemistry platform with its AI-driven and robotics-empowered R&D system, continuously advancing technological upgrades, expanding automated synthesis capacity, and supporting data-driven drug discovery.

Prospects and Outlook

The Group’s “AI + robotics + multi agent” R&D flywheel has achieved both technical validation and commercial deployment in biopharmaceuticals and new materials, and delivering its first full-year profit, marking a new milestone in its platform’s value. Moving ahead, the Group is well positioned to strengthenthe flywheel effect through continuous iteration, consolidating its AI4S leadership via an intelligent closed-loop system built around over 200 end-to-end AI models, high-throughput robotic laboratories, and scalable AI agents, while expanding into consumer health, photovoltaic materials, advanced chemicals sectors and beyond.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

3W Auto-Life Floor Mats Take on Moab’s Famous Red Dust with First Easter Jeep Safari Showcase

Making its debut during the landmark event’s 60th anniversary, 3W Auto-life will showcase premium floor mats designed to fit perfectly in popular Jeep, Ford and many other vehicles

MOAB, Utah, March 25, 2026 /PRNewswire/ — 3W Auto-life, a multi-award-winning brand for premium custom-fit car floor mats, makes its first-ever appearance at the 60th annual Easter Jeep Safari, taking place March 28-April 5, 2026, in Moab, Utah. The brand will sponsor three trail runs across the nine-day event and host a booth at the vendor expo.

3W Auto-Life at Easter Jeep Safari 2026
3W Auto-Life at Easter Jeep Safari 2026

3W will also be showcasing its custom-fit all-weather Jeep and Ford floor mats, as well as running boards (also called truck steps or truck side steps) for Ford F-150 Lightning SuperCrew trucks.

Avid off-road drivers who have spent time on Moab’s trails know one thing for certain: the red dust gets everywhere. It clings to boots, coats the engine and transmission, and finds its way into every corner of a vehicle’s interior.

Set in Moab’s famously dusty conditions, EJS is the perfect stage for 3W’s custom-fit thermoplastic elastomer (TPE) all-weather floor mats to show off its durability and ease of cleaning—directly meeting the demands of the off-road community. At the end of every trail run, the mats can simply be rinsed off, making it a cinch to get rid of sand, mud and dust before the next adventure.

Hitting the Trails—And Protecting Them

Along with sister brand Wolfbox, 3W is sponsoring three guided trail runs organized by Red Rock 4-Wheelers:

  • Hell’s Revenge (level 7) on March 29: dramatic slickrock ridges and steep climbs
  • Moab Rim (level 7) on March 30: technical ledges overlooking the Colorado River gorge
  • Golden Spike (level 7) on March 31: an all‑day endurance gauntlet linking multiple trails

3W brand ambassadors will take part in each of the runs and greet participants at the trailheads, kicking off each day with giveaways and surprises.

On March 29, 3W will also lead a convoy on the Sevenmile Rim run, a popular 13-20 mile moderately difficult (level 4) trail famous for its panoramic views of the La Sal mountains and unique rock formations—eventgoers are encouraged to join.

The sponsorships directly fund trail maintenance and restoration, supporting Moab’s off-road landscape for future generations.

What to Expect at the 3W Booth

The 3W booth at the Old Spanish Trail Arena will be open Thursday, April 2 (10 a.m.–7 p.m.) and Friday, April 3 (9 a.m.–5 p.m.).

3W’s durable, custom-fit TPE floor mats will be showcased on-site in a Jeep Wrangler Rubicon 392—visitors can check out in person how the mats are truly odorless (no chemical smell of traditional rubber), snugly fit into the vehicle, and are a breeze to install, remove and clean. These same mats have variations that are compatible with a wide range of Jeep models—including Wrangler (JKU, JLU and 4XE), Gladiator, Compass, Cherokee and Grand Cherokee—spanning model years 2013–2026.

3W’s product range caters to more than just Jeeps. Owners of popular off-road vehicle brands will be pleased to also see floor mats designed for Ford (such as the F-150, F-150 Lightning SuperCrew, and Bronco models), Toyota, RAM, Chevrolet and GMC.

The brand has even put out floor mats with integrated metal pedals specifically for Ford F-150 (2015–2026) and Ford F-150 Lightning SuperCrew (2022–2025) trucks. These are more durable than competing products and designed to make vehicle entry and exit cleaner and safer in muddy or wet conditions.

On top of the product showcase, booth visitors can decorate miniature 3W Jeep mats, spin a prize wheel, enter raffles, and pick up adventure swag bags and limited edition apparel.

“3W’s floor mats are built for drivers who don’t separate their vehicle from their lifestyle—precision-fitted, all-weather protection that keeps pace with wherever the trail takes you,” said Yucheng Tan, co-founder of 3W Auto-Life.

As an EJS special, 3W is offering 30% off all products with the discount code MOAB30 on the official website: https://3wliners.com/?utm_source=pr&utm_medium=pr&utm_campaign=2026_pr_MOAB30

About 3W Auto-life
Founded in 2015, 3W Auto-life manufactures premium floor mats for over 500 vehicle models across more than 20 major automotive manufacturer partnerships. Its floor mats have earned over 30 design awards—including the prestigious German Red Dot Award—and are trusted by drivers across the United States, Canada, Europe, the United Kingdom, South Korea, Saudi Arabia, and beyond.

For more information, visit 3wliners.com.

CONTACT: 3Wautolife@rootcomms.com 

Auntea Jenny Announces 2025 Annual Results

Focus on High-Quality Growth Recorded Strong Growth on Both Revenue and Profit
Achieve Breakthroughs in Overseas and Fallstea Business Further Consolidate Industry Leadership

Results Highlights

  • Revenue was RMB4,465.64 million, representing a 36.0% year-over-year increase.
  • Gross profit was RMB1,404.23 million, representing a 36.7% year-over-year increase.
  • Profit for the year was RMB501.32 million, representing a 52.4% year-over-year increase.
  • Adjusted profit for the year was RMB570.33 million, representing a 36.4% year-over-year increase.
  • Total stores nationwide surpassed the 10,000-mark, reaching 11,449.
  • The Board recommended the payment of a final dividend of RMB10 per 10 shares (inclusive of tax), aggregating to approximately RMB105.20 million; the total dividend distributed for the full year exceeded RMB176.32 million, to share the fruits of company’s growth with shareholders.

HONG KONG, March 25, 2026 /PRNewswire/ — Auntea Jenny (Shanghai) Industrial Co., Ltd. (“Auntea Jenny” or “the Company“, together with its subsidiaries, the “Group“; stock code: 2589.HK) announced the consolidated annual results for the year ended December 31, 2025 (the “Reporting Period” or the “Year”). During the Reporting Period, the Company recorded revenue of approximately RMB4,465.64 million, representing a 36.0% YoY increase. Gross profit was approximately RMB1,404.23 million, up about 36.7% YoY. Profit for the year reached approximately RMB501.32 million, up 52.4% YoY, and the adjusted profit for the year amounted to approximately RMB570.33 million, up about 36.4% YoY.

In 2025, the Company adhered to its franchise-focused business model and continued to deepen its presence in the lower-tier market, entering a new stage of exceeding ten thousand stores nationwide. Guided by the “Daily Health+” concept, the Group launched a total of 213 new products throughout the year, building differentiated product competitiveness. During the year, the Company focused on enhancing supply chain efficiency and digital transformation to support the efficient operation of its store network. Simultaneously, by deploying multichannel strategies to reach users through multiple dimensions, the membership ecosystem continued to drive repurchase loyalty.

Focusing on lower-tier market expansion and enhancing operational quality at scale

In terms of strategic presence, the Company focuses on the lower-tier market. Its store network covers over 300 cities across China, with stores in third and lower-tier cities accounting for 52.7% of the total as of December 31, 2025, representing a 2.3 percentage points increase year on year, achieving extensive geographical coverage and brand penetration. The freshly-made tea shop market in third and lower-tier cities in China is the largest and is expected to be the fastest-growing segment. In terms of the total number of stores, the Company holds a strong market position among mid-priced freshly-made tea shop brands in the lower-tier market in the PRC. With advantages in terms of store coverage and supply chain network, the Company firmly captures the long-term growth potential of this market.

During the Reporting Period, the Company’s nationwide store network reached 11,449 stores, officially entering a new milestone of exceeding ten thousand stores. While rapidly expanding its store scale, the Company placed great emphasis on the operating quality of its stores and the operational efficiency of its channel network. Adopting its store expansion strategy and upholding the principle of selective expansion and closure, it proactively optimized its network presence and managed, supported and optimized existing stores based on their operating conditions. In the future, the Company will continually focus on improving the quality of store operations and increasing the profitability of stores, assisting franchisees in achieving stable operations and enhancing the service level.

While consolidating its domestic foundation, the Company actively expanded its overseas business in 2025 and opened 45 stores overseas, covering countries including the United States, South Korea, and Malaysia, thereby further expanding its international business footprint.

Building a differentiated brand matrix, driving growth through multi-category innovation

In 2025, guided by the “Daily Health+” Concept, the Company established a diverse range of distinctive products with competitive advantages, and continuously enhanced existing products. It launched a total of 213 new products,which covered a wider range of consumption scenarios and formed a unique competitive edge through diverse product portfolio.

The Auntea Jenny brand successively introduced new products such as the Kale Series of fruit and vegetable tea and the Five-Color Nourishing Bottle Series. By virtue of appealing appearance, rich nutrition and innovative concept of nurturing both body and mind, these products precisely met consumers’ demand for healthy beverages, further strengthening the brand’s health-focused image in the minds of consumers.

At the same time,the Company established coffee as a core product category for the brand’s key promotion by upgrading coffee machine equipment and coffee bean quality. It promoted the integrated innovation in coffee and tea beverages, broadened consumption scenarios and enhanced store operational vitality. Fallstea, with its core research and development concept of “Real Tea, Real Milk”, focused on delivering high-quality and affordable fresh milk tea with real tea leaves. By combining premium ingredients with affordable pricing, it offers a value for money experience and is widely acclaimed by consumers.

Digitalizing the supply chain infrastructure, powering the expansion of store network

Leveraging the substantial procurement demand generated by its large scale store network, the Company continued to strengthen its supply chain bargaining power and management standards, driving the digital and intelligent upgrade of its supply chain operations. This enhanced operational efficiency across the store network and fueled rapid expansion into lower-tier markets.

Regarding procurement, the Company proactively probed into the global origin resources by establishing a direct sourcing model from origin, thereby forging deep and binding partnerships with quality suppliers and OEM manufacturers, comprehensively strengthened the upstream supply chain layout and significantly enhanced the quality stability of core product categories. By building a diversified supply system, it supplemented by in-house production facilities to replenish core material supplies, which provided solid support for the continuity of franchise business.

In terms of logistics and warehousing, the Company established a nationwide supply chain network. It collaborated with independent third-party professional institutions for part of the large-scale warehousing and logistics bases and all of the frontline cold-chain warehouses. This, combined with the coordinated deployment of the self-operated warehousing resources, enables resource complementarity and efficient synergy. As of December 31, 2025, its supply chain network included 16 large warehousing and logistics bases; 4 equipment warehouses; 7 fresh produce warehouses; and 11 frontline cold-chain storage warehouses. During the year,the Group focused on adjusting the warehouse network structure and continuously optimised the distance between warehouses and stores to reduce delivery costs. In the meanwhile, The Company continuously advanced digital and intelligent transformation across the entire chain. It relied on ample transport capacity reserves to efficiently manage the peak periods driven by festive promotions and concentrated orders, providing solid support for the stable operation and scalable expansion of the store network.

Engaging consumers through multi-channel marketing, leveraging member ecosystem to boost repurchase

While continuously upgrading its product offerings, The Company enhanced brand awareness and customer loyalty through digital marketing and a robust membership system. By leveraging a multi-platform matrix, including Xiaohongshu, Douyin, and WeChat, the Company engaged with the public and launched various promotional campaigns to boost brand exposure and customer participation.

Regarding brand identity construction, through celebrity endorsements, it further enhanced brand reputation and market heat, effectively boosting the sales of core product series. At the same time, the Company closely followed market trends and consumer aesthetic preferences,launching trending IP co-branding, which further strengthened consumer recognition and identification with the brand, continuously enhancing  brand’s market appeal.

In terms of member ecosystem,as of December 31, 2025, The Company’s WeChat Mini Program had 154 million registered members, with an average of 17.4 million quarterly active members and a quarterly repurchase rate of 42.5%.

Outlook

1. Channel Diversification: Expanding stores in an orderly manner, and improving single- store profitability

The Company will scientifically screen regional presence grids, implement the store expansion strategy by stages, precisely cater to the needs of different market segments, continuously improve single-store profitability and return on investment, and shorten the investment payback period for franchisees. The Company will adhere to the philosophy of “building mutually beneficial partnership”, improve the franchisee management system, and attract and retain high-quality franchisees with premium products and efficient services.

2. Product Innovation: Keeping pace with consumption trends, and promoting the integration of tea and coffee 

The Company will continuously strengthen the research and development capabilities, closely track consumption trends and industry dynamics, and leverage the deep understanding of consumer preferences to create more blockbuster products. At the same time, it will accelerate the launch of coffee drinks, innovate in consumption scenarios and sales models, and promote the integrated innovation in coffee and tea beverages to activate diversified consumption demands.

3. Supply Chain Upgrade: Enhancing the logistics network and improving supply efficiency

The Company will further strengthen cooperation with high-quality suppliers in China and beyond, increase supply sources, and enhance bargaining power. By optimising supply plans and resource allocation structures, strengthening the coordination of warehousing and distribution, and integrating store expansion plans with the existing warehouse network, the Company will continuously expand the coverage of the cold-chain logistics network, streamline the connection between warehousing and distribution, speed up supply chain responses, and improve cost control, in a bid to provide stable and efficient supply support for stores nationwide.

4. Brand Building: Implementing a differentiated multi-brand strategy, and continuously boosting brand competitiveness

The Company will continue to deepen the multi-brand strategy. Relying on the differentiated positioning of brands, it will penetrate different market segments and increase market share with diversified products, flexible pricing, and various consumption scenarios. Concurrently, the Company will strengthen brand building and market promotion, continuously enhance brand image and awareness, and boost the brand competitiveness.

5. Digitalisation: Strengthening full-process digitalisation, and persistently optimising operations and food safety control

The Company will continuously step up investments in information technology and digitalisation, and integrate digitalisation throughout the entire business process. Specifically, through data analysis, it will improve manpower allocation, operational processes, and decision-making efficiency. Additionally, efforts will be made to leverage digital means to strengthen food safety control, reduce operating costs, and promote the full-chain upgrade to ensure overall efficient operation and compliance.

About Auntea Jenny (Shanghai) Industrial Co., Ltd.

Auntea Jenny (Shanghai) Industrial Co., Ltd. (2589.HK), founded in 2013 and listed on the Hong Kong Stock Exchange in May 2025, is a fast-growing freshly made beverage Company that precisely meets consumer demands through its diverse brand portfolio. It has three major brands, namely Auntea Jenny, Fallstea and Jenny x Coffee. Through its multi-brand portfolio, the Company is able to precisely meet the diverse consumption needs of consumers. The Company operate a franchise-focused business model. Its mutually beneficial franchise system is the foundation for the long-term and stable cooperation with franchisees. In terms of strategic presence, it focuses on the lower-tier market. As of now, the Company has established over 10,000 stores across more than 300 cities nationwide, which holds a strong market position among mid-priced freshly-made tea shop brands in the lower-tier market in the PRC.

Auntea Jenny’s official Website:https://www.hsay.com/

SI Group Earns Silver EcoVadis Rating, Recognized Among Top 15% Globally

Recognition Reflects Progress Detailed in the Company’s 2025 ESG Report

THE WOODLANDS, Texas, March 25, 2026 /PRNewswire/ — SI Group, a leading global developer and manufacturer of performance additives, process solutions, and chemical intermediates, has earned a 2026 Silver sustainability rating from EcoVadis, placing the company in the 85th percentile of all companies assessed worldwide. The recognition marks an improvement from SI Group’s 2025 Bronze rating and reflects the company’s continued progress in advancing its sustainability strategy.

EcoVadis is one of the world’s most widely recognized providers of business sustainability ratings, evaluating companies across four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. In the 2026 assessment, SI Group scored above the industry average in all four categories, demonstrating the company’s commitment to responsible operations and transparent, ethical business practices in chemical manufacturing.

The improved rating builds on the progress outlined in SI Group’s 2025 Environmental, Social, and Governance (ESG) Report, which details measurable achievements across the company’s global operations. SI Group has advanced initiatives focused on reducing greenhouse gas emissions, improving energy efficiency, strengthening responsible resource management, and enhancing supply chain transparency.

In addition to operational improvements, the company has implemented new policies, expanded sustainability programs, and achieved additional certifications that support stronger governance and environmental performance across its global manufacturing network.

“EcoVadis provides an important benchmark for evaluating our sustainability performance and identifying opportunities to continue improving,” said Mike Farnell, SVP General Counsel and Chief Sustainability Officer. “Achieving a Silver rating is an encouraging milestone that reflects the dedication of our teams worldwide to operating responsibly and supporting our customers with solutions that contribute to a more sustainable future.”

SI Group continues to integrate sustainability across the development, manufacture, and application of its chemical technologies, helping customers meet evolving performance and environmental goals while maintaining a strong focus on safety, compliance, and responsible growth.

For more information about SI Group’s sustainability initiatives, visit www.siigroup.com/sustainability or read the company’s 2025 ESG Report.

About SI Group
SI Group is a global leader in performance additives, process solutions, and chemical intermediates. SI Group’s chemistries are essential solutions that enhance the quality and performance of industrial and consumer goods in the plastics, rubber and adhesives, fuels, lubricants, coatings, and oilfield industries. Headquartered in The Woodlands, Texas, SI Group operates 18 manufacturing facilities across three continents and serves customers in more than 80 countries, supported by approximately 1,500 employees worldwide. Driven by a passion for safety, chemistry, sustainability, and delivering extraordinary results, SI Group innovates to create long-term value for a better future. Learn more at www.siigroup.com.

About EcoVadis
EcoVadis is a purpose-driven company dedicated to embedding sustainability intelligence into every business decision worldwide. In 2024, EcoVadis acquired Ulula, a leading worker voice platform that strengthens its capabilities in supporting human rights due diligence. With global, trusted and actionable ratings, businesses of all sizes rely on EcoVadis’ detailed insights to comply with ESG regulations, reduce GHG emissions, and improve the sustainability performance of their business and value chain across 250 industries in 185 countries. Leaders like Johnson & Johnson, L’Oréal, Unilever, Bridgestone, BASF and JPMorgan are among 150,000+ businesses that use EcoVadis ratings, risk, and carbon management tools and e-learning platform to accelerate their journey toward resilience, sustainable growth and positive impact worldwide. Learn more on ecovadis.com

Media Contact:
Joseph Grande
ph: + 1.413.684.2463
joe@jgrandecommunications.com

Waterdrop Filter Launches Spring Promotion to Refresh Home Water Quality

LOS ANGELES, March 25, 2026 /PRNewswire/ — Waterdrop Filter, a global leader in water purification technology, is launching its Spring Promotion across the U.S  from March 25 to 31, featuring a lineup of high-performance filtration systems with special discounts. The campaign highlights practical, easy-to-integrate solutions that address everyday water concerns while supporting healthier living.

As temperatures rise and daily routines shift, spring often prompts a reset in how people approach health and home environments. Seasonal cleaning, along with increased concerns around allergies and skin sensitivity, is bringing renewed attention to water quality. At the same time, issues such as PFAS contamination, aging pipes, and bottled water safety continue to shape consumer awareness.

In response, Waterdrop Filter is introducing spring discounts across its popular best-selling products to help address common water concerns, including PFAS, lead, and infrastructure-related risks.

  • Waterdrop G3P800 Tankless Reverse Osmosis System: Designed for medium to large households, this NSF/ANSI 42, 53, 58 & 372 certified system features 10-stage filtration, 800 GPD capacity, and UV sterilization, reducing 98% of PFOA, 99% of PFOS, and over 99% of lead while saving under-sink space with its tankless design. Now available at $699 (originally $999).
  • Waterdrop X12 Under-sink RO System: Built for high-demand homes, this flagship model offers 1200 GPD flow and 11-stage filtration that removes key contaminants (98.88% PFOA and 98.97% PFOS reduction) while retaining beneficial minerals for improved taste and daily use. Now available at $899 (originally $1299).
  • Waterdrop DLG-P Under Sink Water Filter System: A practical option for renters and first-time users, this system installs in minutes and features a dual-outlet design with strong PFAS reduction, including 99.7% PFOA and 99.6% PFOS removal. Now available at $99.99 (originally $119.99).
  • Waterdrop TSU Ultrafiltration System: A compact, eco-friendly solution that requires no electricity and produces zero wastewater. Its three-stage filtration helps reduce heavy metals such as lead while maintaining everyday usability. Now available at $139.99 (originally $189.99).
  • Waterdrop Glass Water Filter Pitcher: A simple, no-install option made from high-quality glass, featuring five-stage filtration that reduces PFAS, chlorine, and heavy metals, ideal for daily hydration upgrades. Now available at $44.99 (originally $49.99).

With spring renewal underway, Waterdrop Filter encourages households to include water quality in home refresh priorities. By making trusted filtration solutions more accessible during this limited-time promotion, the brand aims to deliver reliable solutions and help households take a proactive approach to everyday water quality.For more information, consumers can explore available offers through Waterdrop Filter’s official website and Amazon store.

About Waterdrop Filter

Founded in 2015, Waterdrop Filter is a water purification company that offers solutions for homes, offices, and outdoor use. Its product range includes under-sink and countertop Reverse Osmosis (RO) systems, pitchers, and whole-house filters. With the mission of making clean water accessible worldwide, Waterdrop Filter provides water filtration products trusted by over 40 million families globally. Learn more from www.waterdropfilter.com

Waterdrop Filter Spring Promotion
Waterdrop Filter Spring Promotion

 

Wolfbox® Debuts at 60th Easter Jeep Safari With Off-Road Visibility Tech Showcase

Also a sponsor for three iconic Moab trail runs at America’s premier off-road event, Wolfbox will host an interactive booth to spotlight the brand’s off-road visibility technology and trail-ready gear.

MOAB, Utah, March 25, 2026 /PRNewswire/ — Wolfbox, a leader in off-road dash cams and automotive electronics, will make its debut appearance at the Easter Jeep Safari (EJS) this year, just as the landmark off-road event celebrates its 60th anniversary.

Taking place March 28 to April 5, 2026, in Moab, Utah, the annual event—one of the most influential off-road gatherings in North America—will see Wolfbox sponsor three trail runs, with the donations directly supporting Moab trail restoration and maintenance.

Wolfbox at Easter Jeep Safari 2026
Wolfbox at Easter Jeep Safari 2026

With EJS gathering off-roaders from far and wide in one place, Wolfbox is able to show off on-site at its vendor expo booth how its suite of trail-ready technology are designed to serve this niche community. The brand will showcase products including the world’s first bumper-mounted smart mirror dash cam, the G900 Tripro Bumper Version; the soon-to-launch Hypeflow 60D tire inflator; and the popular MegaFlow 200 cordless air duster.

Three Iconic Trails Sponsored by Wolfbox

Wolfbox will sponsor three well-known guided trail runs organized by Red Rock 4-Wheelers:

  • Hell’s Revenge (level 7) on March 29: dramatic slickrock ridges and steep climbs
  • Moab Rim (level 7) on March 30: technical ledges overlooking the Colorado River gorge
  • Golden Spike (level 7) on March 31: an all‑day endurance gauntlet linking multiple trails

Wolfbox brand ambassadors and well-known off-road enthusiasts Shaun (@TheStoryTillNow on YouTube), Austin (@jku392adventures on YouTube), and Ted (@expeditionteamwiborn on Instagram) will participate in the three sponsored runs, demonstrating how the G900 Tripro’s front bumper cam gives drivers a clear view of every upcoming obstacle.

The sponsorships directly fund trail maintenance and restoration, supporting Moab’s off-road landscape for future generations.

On March 29, Wolfbox brand ambassador Ted will also lead the brand’s off-road vehicle team on the Sevenmile Rim run, a popular 13-20 mile moderately difficult (level 4) trail famous for its panoramic views of the La Sal mountains and unique rock formations—eventgoers are encouraged to join.

Drivers at each Wolfbox trail starting line will be greeted with Wolfbox surprises and commemorative giveaways.

Product Demos and Prizes at the Wolfbox Booth

The Wolfbox booth at the Old Spanish Trail Arena (3641 S Hwy 191, Moab, UT) will be open Thursday, April 2 (10 a.m.-7 p.m.) and Friday, April 3 (9 a.m.-5 p.m.).

At the “Heroes, We Invite You!” booth experience, visitors can check out Wolfbox’s star products for themselves or watch the Wolfbox team put them through their paces in a Jeep Wrangler Rubicon 392. Showcased products include:

  • The world’s first bumper-mounted smart mirror dash cam, the G900 Tripro Bumper Version, which solves a common off-road problem: blind spots caused by steep terrain and oversized spare tires. Its live three-camera feed—4K front, 2.5K rear, and 1080p bumper—delivers complete trail visibility, and visitors are welcome to see the camera angles and experience the system firsthand.
  • The new, soon-to-launch Hypeflow 60D tire inflator, which features a high-efficiency dual-blade fan cooling system with a 100% duty cycle at 40 PSI and up to 60 minutes of continuous runtime.
  • The MegaFlow 200 cordless air duster, which delivers up to 270 g of air pressure at 71 m/s across three speed settings—built for extended trail use.

Booth visitors can pick up brand swag bags, enter raffle draws to win premium Wolfbox products, purchase limited edition apparel, and check out the debut of Wolfbox’s new brand mascot.

With brand ambassadors Shaun (10 a.m.-11 a.m. on April 2), Austin (all day on April 2), and Ted (all day on April 3) on hand at the Wolfbox booth during EJS, visitors and fans can also stop by to meet and chat with them in person.

“Easter Jeep Safari represents the pinnacle of the off-road spirit—a community of passion, challenge and storytelling,” said Wolfbox CEO Jonny Tang.

“Participating in the event’s 60th anniversary milestone is about more than just showcasing Wolfbox’s products—it’s about connecting directly with the trail-blazers who inspire our innovation and drive us to keep pushing the boundaries of off-road technology.”

About Wolfbox
Founded in 2019, Wolfbox is a leading brand in automotive electronics that specializes in advanced smart mirrors and dash cams, as well as other auto accessories such as jump starters, tire inflator and deflators, 2-in-1 starter and compressors, and more. Wolfbox has served over 800,000 drivers in 89 countries, and continues to innovate and revolutionize the auto accessories market with high-tech automotive gadgets and electronics for tech-savvy consumers and outdoor activity enthusiasts.

For more information, visit wolfbox.com.

CONTACT: wolfbox@rootcomms.com 

Trusted by 10 Million Users: HBADA Launches the HBADA E3 Series 2026 Edition, Crowning the Ultimate $500-Class Ergonomic Office Chair for U.S. Consumers

Backed by 16 years of ergonomic export excellence, German IGR certifications, and glowing reviews from top U.S. desk setup experts, the all-new HBADA E3 Series 2026 Edition is redefining affordable premium seating for the American home office. Available now.

LOS ANGELES, March 25, 2026 /PRNewswire/ — HBADA, a globally recognized leader in workspace seating solutions, today announced the United States launch of its highly anticipated HBADA E3 Series 2026 Edition. Built upon an impressive legacy of 16 years of specialized expertise in ergonomics and chosen by over 10 million users worldwide, HBADA is bringing its most refined, trustworthy, and value-driven flagship ergonomic chairs to the American market.

HBADA E3 Series 2026 Edition
HBADA E3 Series 2026 Edition

Rather than chasing flashy tech gimmicks, HBADA has spent over a decade perfecting the fundamentals of ergonomic comfort for long hours of sitting. The HBADA E3 Series 2026 Edition is the culmination of this sincere, user-first initiative, offering premium, maintenance-free support and heavy-duty build quality at a highly accessible price point for U.S. hybrid workers, gamers, and professionals. The core philosophy driving this new lineup is simple: Precision Mechanics, Bio-Synchronized Support.

“Our philosophy is simple: sincerity in product creation backed by rigorous testing,” said the Head of Overseas Marketing & Sales at HBADA. “With 16 years of engineering experience and the trust of 10 million global customers, we know what it takes to build an ergonomic office chair that lasts. We are proud to declare that the HBADA E3 Pro 2026 Edition is, without a doubt, the most capable, durable, and comfortable desk chair you can buy in the U.S. in the $500 class.”

Validated by Global Standards and Leading U.S. Ergonomic Experts 
The HBADA E3 Series 2026 Edition is strictly certified by the prestigious German IGR Institute for Health and Ergonomics. Furthermore, these heavy-duty mesh chairs are fully compliant with rigorous BIFMA durability standards—exceeding requirements with over 120,000 fatigue cycles tested—featuring SGS Class-4 Gas Lifts to ensure absolute safety for the American demographic.

This dedication to quality has caught the attention of the harshest critics in the U.S. tech review space. Leading ergonomic experts at BTOD.com / BTOD tv noted,  “In terms of its implementation, in terms of how springy and comfortable it feels, it actually feels pretty darn good.”  Popular YouTube tech and setup reviewer Ahnestly praised its responsive design: “If you really value a footrest, a good headrest, and overall adjustability in a chair, then this could be a great fit.”

The HBADA E3 Series 2026 Edition: Unbeatable Value and Craftsmanship 
The U.S. launch lineup features two meticulously crafted models, proving that premium ergonomics shouldn’t require a premium price tag:

HBADA E3 Pro 2026 Edition – The Ultimate $500-Class Flagship Chair:

  • 3-Zone Elastic Lumbar Support System: Perfected for back pain relief, this mechanism features zero-lag tracking, an 80° auto-wrap, and 5° dynamic tracking to provide sincere, hands-like lateral support all day long.
  • 720° Omni-Mechanical Arm: Defy spatial limits. Built for modern setups, these arms rotate dual 360° and flip up 26° and down 13°, providing a perfect hovering anchor for your elbows whether you are typing or gaming.
  • Tailored Fit for the U.S.: Engineered for 5’1″ to 6’5″ (155cm – 195cm), featuring a 70mm deep-dive Dual-Axis Headrest and an 80mm backrest lift, it solidly adapts to a wide range of body types with ease.

HBADA E3 Air 2026 Edition – The Unrivaled Everyday Performer:

  • 140° Zero-Gravity Recline: A deeply relaxing recline with 5 solid locking positions, creating the ultimate mid-day recharge pod.
  • Upgraded CloudMesh™: An extensively tested 4-Way Elastic Weave that provides 83% more breathability than standard office chairs, keeping you cool for 8+ hours.

Official U.S. Launch: Limited Inventory Available Now 
Following a highly anticipated pre-order phase, the HBADA E3 Series 2026 Edition is officially available and shipping to U.S. customers starting March 25th.

Due to overwhelming demand from our early subscriber base, our initial U.S. inventory is strictly limited. We encourage professionals and gamers to act quickly to secure their ultimate ergonomic upgrade before the first production batch sells out.

Secure Your Unit Now:

Official Launch Pricing (MSRP):

  • HBADA E3 Air 2026 Edition: Starting at $399 (Varies by color)
  • HBADA E3 Pro 2026 Edition: Starting at $549 (The Ultimate $500-Class Flagship)

About HBADA 
With 16 years of dedication to ergonomic excellence and over 10 million satisfied users globally, HBADA is committed to sincere craftsmanship. Certified by strict international standards (BIFMA, German IGR), HBADA focuses on delivering the highest quality ergonomic office chairs that support the health of modern professionals.

 

Tintri and Platform9 Announce Joint Solution for containerized and hypervisor-based workloads.

New all-in-one platform to help businesses develop and deploy at scale with maximum ROI


CHATSWORTH, US – Media OutReach Newswire – 25 March 2026 – Tintri, the innovator in workload-aware, AI-powered data management, and Platform9, the leader in simplifying enterprise private clouds, today announced a strategic partnership to deliver a bundled AI-ready infrastructure solution that streamlines deployment and reduces operational costs. The out-of-the-box offering makes it simple for enterprises to stand up and scale modern AI systems without the complexity of traditional stacks.

The Problem: AI Is Getting Expensive

Running AI to process and analyze data in real time, requires moving enormous amounts of data at extremely high speeds. Existing infrastructure wasn’t built to manage the sheer volume and velocity of data required for on-demand inferencing and ongoing model training, ultimately causing slowdowns and driving up operational costs. Tintri and Platform9 directly addresses these critical bottlenecks in the by cutting the cost per AI transaction, as low as possible.

What’s in the New Platform

The new offering has two main parts:

1. A powerful data center component built on standard server hardware that can run multiple types of virtual machines and containerized applications side-by-side, without resource impacts. Tintri’s patented technology monitors each application individually, making sure the most critical ones always get the resources they need.

2. An edge AI component designed for capturing real-time data to continuously learn and update inference models.

A core component of the platform is Tintri VMstore, which uniquely runs multiple virtualization platforms and Kubernetes (the industry-standard system for managing containerized applications) all within the same platform. This is a significant differentiator: most competing solutions require separate infrastructure for each. Tintri’s patented technology observes each application individually and guarantees real-time resource delivery, even when the system is under heavy load. This eliminates the “noisy neighbor” problem, where resource-intensive applications steal resources and slow down everything else.

Why It Matters

Many companies today have AI running in multiple locations, either in a central data center, as well as out in the field on cameras, sensors, or other devices. Managing all of that separately is complex and expensive. This new platform unifies the entire setup under one management system (provided by Platform9), so IT teams spend less time juggling tools and more time moving their business forward.

Available now through Tintri’s global network of authorized partners, Phil Trickovic, Senior Vice President of Tintri said:“This launch represents a major milestone in our commitment to providing intelligent, autonomous infrastructure. We’re giving customers the exact tools they need to conquer the complexities of modern AI and edge computing, all while driving down operational costs.”

Hashtag: #Tintri #Platform9

The issuer is solely responsible for the content of this announcement.

About Tintri

Tintri delivers the industry’s only workload-aware, AI-powered data management platform, built specifically for virtualized and containerized workloads. Its VMstore platform autonomously manages data at the level of individual VMs, containers, and databases; providing per-workload automation, guaranteed QoS, and predictive analytics that eliminate routine tuning and troubleshooting. Recognized for this innovative approach, Tintri was named “Overall Data Storage Company of the Year” in the 2025 Data Breakthrough Awards. Learn more at .

About Platform9

Platform9 is the leader in simplifying enterprise private clouds. The company’s flagship product, Private Cloud Director, has all of VMware’s enterprise-grade features today along with private cloud features for the future. Platform9 was founded by a team of VMware cloud pioneers and has over tens of thousands of nodes in production at some of the world’s largest enterprises. Platform9 is an inclusive, globally distributed company backed by prominent investors, committed to driving private cloud innovation and efficiency. For more information, go to: .